Resolved hepatitis B is associated with higher reactivation risk than chronic infection after chemoembolization for hepatocellular carcinoma

Figure 1 Cumulative incidence of hepatitis B virus reactivation after transarterial chemoembolization. A: Cumulative incidence stratified according to presence/absence of baseline hepatitis B virus (HBV) DNA (detectable, n = 541; undetectable, n = 435); B: Cumulative incidence stratified according to number of transarterial chemoembolization sessions (at least three sessions, n = 302; fewer than three sessions, n = 674); C: Cumulative incidence stratified according to baseline HBV status: Chronic HBV infection (hepatitis B surface antigen-positive, n = 727) and resolved HBV infection (hepatitis B surface antigen-negative/antibody to hepatitis B core antigen-positive, n = 47). Patients for whom serological data were incomplete (n = 202) were excluded. Shaded areas represent 95% confidence intervals. HBV: Hepatitis B virus; TACE: Transarterial chemoembolization.